vs
Side-by-side financial comparison of LCNB CORP (LCNB) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $23.0M, roughly 1.0× Intellia Therapeutics, Inc.). LCNB CORP runs the higher net margin — 23.7% vs -416.2%, a 439.9% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 5.1%). LCNB CORP produced more free cash flow last quarter ($33.4M vs $-69.4M). Over the past eight quarters, LCNB CORP's revenue compounded faster (15.7% CAGR vs -10.8%).
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
LCNB vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.9M | $23.0M |
| Net Profit | $5.7M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 29.2% | -428.9% |
| Net Margin | 23.7% | -416.2% |
| Revenue YoY | 5.1% | 78.8% |
| Net Profit YoY | -7.6% | 25.7% |
| EPS (diluted) | $0.40 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.9M | $23.0M | ||
| Q3 25 | $23.8M | $13.8M | ||
| Q2 25 | $22.8M | $14.2M | ||
| Q1 25 | $21.5M | $16.6M | ||
| Q4 24 | $22.7M | $12.9M | ||
| Q3 24 | $21.4M | $9.1M | ||
| Q2 24 | $19.3M | $7.0M | ||
| Q1 24 | $17.8M | $28.9M |
| Q4 25 | $5.7M | $-95.8M | ||
| Q3 25 | $6.9M | $-101.3M | ||
| Q2 25 | $5.9M | $-101.3M | ||
| Q1 25 | $4.6M | $-114.3M | ||
| Q4 24 | $6.1M | $-128.9M | ||
| Q3 24 | $4.5M | $-135.7M | ||
| Q2 24 | $925.0K | $-147.0M | ||
| Q1 24 | $1.9M | $-107.4M |
| Q4 25 | 29.2% | -428.9% | ||
| Q3 25 | 35.6% | -808.9% | ||
| Q2 25 | 31.6% | -772.2% | ||
| Q1 25 | 25.6% | -726.6% | ||
| Q4 24 | 32.9% | -1059.9% | ||
| Q3 24 | 24.9% | -1589.0% | ||
| Q2 24 | 4.9% | -1998.6% | ||
| Q1 24 | 12.5% | -394.0% |
| Q4 25 | 23.7% | -416.2% | ||
| Q3 25 | 29.1% | -735.2% | ||
| Q2 25 | 26.0% | -710.8% | ||
| Q1 25 | 21.4% | -687.6% | ||
| Q4 24 | 27.0% | -1001.2% | ||
| Q3 24 | 21.2% | -1489.5% | ||
| Q2 24 | 4.8% | -2112.6% | ||
| Q1 24 | 10.7% | -371.3% |
| Q4 25 | $0.40 | $-0.81 | ||
| Q3 25 | $0.49 | $-0.92 | ||
| Q2 25 | $0.41 | $-0.98 | ||
| Q1 25 | $0.33 | $-1.10 | ||
| Q4 24 | $0.44 | $-1.27 | ||
| Q3 24 | $0.31 | $-1.34 | ||
| Q2 24 | $0.07 | $-1.52 | ||
| Q1 24 | $0.15 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.6M | $449.9M |
| Total DebtLower is stronger | $104.4M | — |
| Stockholders' EquityBook value | $273.9M | $671.4M |
| Total Assets | $2.2B | $842.1M |
| Debt / EquityLower = less leverage | 0.38× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.6M | $449.9M | ||
| Q3 25 | $35.9M | $511.0M | ||
| Q2 25 | $49.8M | $459.7M | ||
| Q1 25 | $37.7M | $503.7M | ||
| Q4 24 | $35.7M | $601.5M | ||
| Q3 24 | $39.4M | $658.1M | ||
| Q2 24 | $34.9M | $691.1M | ||
| Q1 24 | $33.0M | $791.3M |
| Q4 25 | $104.4M | — | ||
| Q3 25 | $104.7M | — | ||
| Q2 25 | $105.0M | — | ||
| Q1 25 | $104.6M | — | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $155.7M | — | ||
| Q2 24 | $162.2M | — | ||
| Q1 24 | $162.6M | — |
| Q4 25 | $273.9M | $671.4M | ||
| Q3 25 | $269.9M | $748.4M | ||
| Q2 25 | $263.5M | $715.3M | ||
| Q1 25 | $258.7M | $779.9M | ||
| Q4 24 | $253.0M | $872.0M | ||
| Q3 24 | $253.2M | $962.6M | ||
| Q2 24 | $245.2M | $971.1M | ||
| Q1 24 | $233.7M | $1.0B |
| Q4 25 | $2.2B | $842.1M | ||
| Q3 25 | $2.2B | $925.3M | ||
| Q2 25 | $2.3B | $898.9M | ||
| Q1 25 | $2.3B | $986.2M | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.3B | $1.2B | ||
| Q2 24 | $2.4B | $1.2B | ||
| Q1 24 | $2.3B | $1.3B |
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.4M | $-69.3M |
| Free Cash FlowOCF − Capex | $33.4M | $-69.4M |
| FCF MarginFCF / Revenue | 140.2% | -301.6% |
| Capex IntensityCapex / Revenue | 4.0% | 0.5% |
| Cash ConversionOCF / Net Profit | 6.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | $54.5M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.4M | $-69.3M | ||
| Q3 25 | $14.0M | $-76.9M | ||
| Q2 25 | $5.5M | $-99.6M | ||
| Q1 25 | $2.2M | $-148.9M | ||
| Q4 24 | $93.2M | $-85.2M | ||
| Q3 24 | $11.9M | $-84.8M | ||
| Q2 24 | $54.9M | $-58.2M | ||
| Q1 24 | $-11.9M | $-120.7M |
| Q4 25 | $33.4M | $-69.4M | ||
| Q3 25 | $13.7M | $-76.9M | ||
| Q2 25 | $5.2M | $-99.9M | ||
| Q1 25 | $2.1M | $-149.7M | ||
| Q4 24 | $89.4M | $-86.2M | ||
| Q3 24 | $10.5M | $-86.1M | ||
| Q2 24 | $53.8M | $-59.2M | ||
| Q1 24 | $-12.8M | $-123.2M |
| Q4 25 | 140.2% | -301.6% | ||
| Q3 25 | 57.4% | -558.2% | ||
| Q2 25 | 23.0% | -701.0% | ||
| Q1 25 | 10.0% | -900.1% | ||
| Q4 24 | 394.0% | -669.4% | ||
| Q3 24 | 49.0% | -945.2% | ||
| Q2 24 | 278.6% | -850.9% | ||
| Q1 24 | -71.8% | -425.7% |
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 1.3% | 0.2% | ||
| Q2 25 | 1.0% | 1.7% | ||
| Q1 25 | 0.3% | 4.4% | ||
| Q4 24 | 16.7% | 7.6% | ||
| Q3 24 | 6.7% | 14.0% | ||
| Q2 24 | 5.9% | 14.5% | ||
| Q1 24 | 4.8% | 8.7% |
| Q4 25 | 6.08× | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 15.23× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 59.35× | — | ||
| Q1 24 | -6.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LCNB
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
